July 11, 2019

FDA to Review Isatuximab as a Potential Treatment for R/R Multiple Myeloma

PARIS – July 10, 2019 – The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational monoclonal antibody that targets a specific […]

Read more

March 1, 2019

Oncology Meeting Innovations holds 2nd Annual Global Summit on Hematologic Malignancies: Europe

Oncology Meeting Innovations held it’s 2nd Annual Global Summit on Hematologic Malignancies: Europe in Lisbon, Portugal from February 14 -16, 2019. Dr. Giovanni Martinelli of Istituto Scientifico Romagnolo, Dr. Maria-Victoria Mateos of University of Salmanaca and Dr. Davide Rossi of the Institute of Oncology Research chaired the Summit. Tumor types covered within the agenda included […]

Read more

January 14, 2019

FDA’s approval of Cabometyx was based on results from the phase III pivotal trial of Cabometyx for patients with advanced HCC who received prior sorafenib

ALAMEDA, Calif.–(BUSINESS WIRE)–Jan. 14, 2019– Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S.1 “This new indication for CABOMETYX is […]

Read more